Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilastine vs Levocetirizine in Chronic Idiopathic Urticaria
NCT00421109Phase 3Completed
- Sponsor
- Faes Farma
- Start
- Jul 2006
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of bilastine in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Faes Farma. Primary endpoint: Total Symptom Score at 28 days. Started Jul 2006; status: completed.
02
Drugs
bilastine
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NCT00421109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421109.